An Open-label Study to Investigate the Tolerability, Pharmacokinetics and Anti-tumour Effect Following Photodynamic Therapy (PDT) With Single-ascending Doses of LUZ11 in Patients With Advanced Head and Neck Cancer

Trial Profile

An Open-label Study to Investigate the Tolerability, Pharmacokinetics and Anti-tumour Effect Following Photodynamic Therapy (PDT) With Single-ascending Doses of LUZ11 in Patients With Advanced Head and Neck Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Redaporfin (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions; First in man
  • Sponsors Luzitin
  • Most Recent Events

    • 02 Jun 2017 Results (n=13) form phase I portion of the study, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 01 Mar 2016 Planned End Date changed from 1 Dec 2014 to 1 Jul 2016, according to ClinicalTrials.gov record.
    • 01 Mar 2016 Planned primary completion date changed from 1 Oct 2014 to 1 Jul 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top